Dr. Ottosen brings fifteen years of experience in the identification of nucleic acid-based medicine candidates for clinical development to Sixfold. He was previously a senior leader at the Roche Innovation Center in Copenhagen, where he was instrumental in bringing three nucleic acid-based medicines from idea to clinical testing. Prior to Roche, Dr. Ottosen was a Senior Research Scientist at Santaris Pharma, playing a key role in the discovery and preclinical testing of locked-nucleic acid-based antisense therapeutics for both internal projects and in partnerships. 

“I’ve seen first-hand the success of therapeutic oligonucleotides in the relatively limited tissue space that supports uptake of this type of molecules,” says Dr. Ottosen. “The next wave is to bring this success to tissues that have not previously been tractable, and that is what Sixfold Biosciences offers to solve with the Mergo technology.”

“Søren has extensive experience in progressing molecules with novel mechanisms of action from the lab into the clinic, and these are key skills we will need as we advance our RNA delivery vehicles for both our internal pipeline and partnered assets,” says Dr Anna Perdrix Rosell, co-founder and co-CEO of Sixfold Bioscience. “We are thrilled to have him driving our research strategy and execution.”

Biography

Søren Ottosen is an early drug discovery program manager, strategy and project leader with 15 years of experience in identifying nucleic acid-based medicine candidates for clinical development, first at Santaris Pharma as a Senior Research Scientist and then at the Roche Innovation Center Copenhagen. While at Roche, Dr. Ottosen held a number of positions, including Senior Portfolio and Platform Development Leader and Senior Leader. Dr. Ottosen received his Bachelor of Science from the Institute of Molecular Biology at the University of Copenhagen, his Ph.D from the Department of Biochemistry and Molecular Biology at Michigan State University, and did his postdoctoral fellowship in the Department of Microbiology at NYU School of Medicine. 

Sixfold Biosciences is a biotechnology company solving one of the most critical challenges preventing the greater utilization of powerful RNA medicines: delivery. Sixfold’s solution takes evolution as inspiration, learning and mimicking how RNA is naturally delivered to different cell types in the body. Using advanced AI and Bayesian Optimization, Sixfold is learning the language that encodes RNA-shuttle interactions and destination selection, unlocking new cell types for treatment.